Dexcom Outlines Three-Pronged Growth Strategy To Reach $4-4.5BN Revenue Goal By 2025
Dexcom’s growth strategy includes growing its core business, expanding into pharmacy sales channel, and expanding into new markets.
You may also be interested in...
Exec Chat: Dexcom’s CEO Bullish On Year Ahead With G7 CGM Launch, Dexcom One CGM Expansion
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.
JPM 2021: Boston Scientific, Abbott, Dexcom, Insulet, Silk Road Medical
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
Device Week, 10 December 2020 – LivaNova Divests Valves; Experts Address ‘Metabesity’
In this week’s podcast: LivaNova sells its heart valve business to a private equity firm, an expert panel discusses the challenges of addressing so-called “metabesity,” and Dexcom explains its plans to double its revenue over the next few years.